Price Alert

InMed Pharmaceuticals Inc... (INM)

NASDAQ: INM · Real-Time Price · USD

2.29

0.03 (1.33%)

At close: Oct 03, 2025, 3:59 PM

2.24

-2.18%

After-hours: Oct 03, 2025, 06:47 PM EDT

1.33% (1D)

Bid	2.25
Market Cap	4.59M
Revenue (ttm)	4.94B
Net Income (ttm)	-1.73M
EPS (ttm)	-8.36
PE Ratio (ttm)	-0.27
Forward PE	n/a
Analyst	n/a
Dividends	n/a

Ask	2.31
Volume	54,346
Avg. Volume (20D)	92,906
Open	2.22
Previous Close	2.26
Day's Range	2.22 - 2.29
52-Week Range	1.72 - 8.27
Beta	0.38
Ex-Dividend Date	n/a

About INM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol INM

Website n/a

Full Company Profile

Why Price Moved

3 months ago

+57.96%

InMed shares are trading higher after the company ... Unlock content with Pro Subscription

8 months ago

+2.02%

InMed Pharmaceuticals shares are trading higher after the company announced that INM-901 reduced Alzheimer 's-related inflammation in a preclinical study.

News

1 week ago · newsfilecorp.com

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-rel...

1 month ago · newsfilecorp.com

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...

2 months ago · newsfilecorp.com

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc....